<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002258.pub2" GROUP_ID="MOVEMENT" ID="101599101310253877" MERGED_FROM="" MODIFIED="2008-11-13 16:18:17 +0100" MODIFIED_BY="Ema Roque" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Short title (no longer in use): Bromocriptine monotherapy in Parkinson's disease&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-13 15:16:34 +0000" NOTES_MODIFIED_BY="Ema Roque" REVIEW_NO="001" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-11-13 16:18:17 +0100" MODIFIED_BY="Ema Roque">
<TITLE>Bromocriptine versus levodopa in early Parkinson's disease</TITLE>
<CONTACT MODIFIED="2008-11-13 16:18:17 +0100" MODIFIED_BY="Ema Roque"><PERSON ID="14835" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME/><MIDDLE_INITIALS>JJ</MIDDLE_INITIALS><LAST_NAME>van Hilten</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>j.j.van_Hilten@lumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Leiden University of Medical Center</ORGANISATION><ADDRESS_1>Albinusdreef 2</ADDRESS_1><CITY>Leiden</CITY><ZIP>2333 ZA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 71 526 2134</PHONE_1><FAX_1>+31 71 524 8253</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-13 16:18:17 +0100" MODIFIED_BY="Ema Roque"><PERSON ID="14835" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME/><MIDDLE_INITIALS>JJ</MIDDLE_INITIALS><LAST_NAME>van Hilten</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>j.j.van_Hilten@lumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Leiden University of Medical Center</ORGANISATION><ADDRESS_1>Albinusdreef 2</ADDRESS_1><CITY>Leiden</CITY><ZIP>2333 ZA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 71 526 2134</PHONE_1><FAX_1>+31 71 524 8253</FAX_1></ADDRESS></PERSON><PERSON ID="14828" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Claudia</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Ramaker</LAST_NAME><EMAIL_1>crag@hetnet.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Leiden University of Medical Center</ORGANISATION><ADDRESS_1>P.O. Box 9600</ADDRESS_1><CITY>Leiden</CITY><ZIP>2300 RC</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="18323" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rebecca</FIRST_NAME><LAST_NAME>Stowe</LAST_NAME><POSITION>Senior Systematic Reviewer</POSITION><EMAIL_1>r.l.harrison@bham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>University of Birmingham Clinical Trials Unit</DEPARTMENT><ORGANISATION>University of Birmingham</ORGANISATION><ADDRESS_1>Division of Medical Sciences, Robert Aitken Institute</ADDRESS_1><ADDRESS_2>Edgbaston</ADDRESS_2><CITY>Birmingham</CITY><ZIP>B15 2TT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 121 415 9106</PHONE_1><PHONE_2>+44 121 415 9113</PHONE_2><FAX_1>+44 121 415 9135</FAX_1></ADDRESS></PERSON><PERSON ID="18322" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Natalie</FIRST_NAME><LAST_NAME>Ives</LAST_NAME><POSITION>Senior Statistician</POSITION><EMAIL_1>n.j.ives@bham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>University of Birmingham Clinical Trials Unit</DEPARTMENT><ORGANISATION>University of Birmingham</ORGANISATION><ADDRESS_1>Division of Medical Sciences, Robert Aitken Institute</ADDRESS_1><ADDRESS_2>Edgbaston</ADDRESS_2><CITY>Birmingham</CITY><ZIP>B15 2TT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 121 415 9113</PHONE_1><PHONE_2>+44 121 415 9106</PHONE_2><FAX_1>+44 121 415 9135</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-13 15:15:53 +0000" MODIFIED_BY="Ema Roque" NOTES="&lt;p&gt;Minor update: 18/02/00&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 03/04/07&lt;/p&gt;" NOTES_MODIFIED="2008-11-13 15:15:53 +0000" NOTES_MODIFIED_BY="Ema Roque">
<UP_TO_DATE>
<DATE DAY="20" MONTH="8" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="4" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="8" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW NOTES="&lt;p&gt;A literature update has been performed.&lt;br&gt;No eligible trials were identified for inclusion.&lt;/p&gt;">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="13" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="20" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Prinses Beatrix Fonds</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-13 15:11:37 +0000" MODIFIED_BY="Ema Roque">
<SUMMARY MODIFIED="2008-11-13 15:11:37 +0000" MODIFIED_BY="Ema Roque">
<TITLE MODIFIED="2008-11-13 15:11:37 +0000" MODIFIED_BY="Ema Roque">Bromocriptine versus levodopa in early Parkinson's disease</TITLE>
<SUMMARY_BODY>
<P>Parkinson's disease is a disabling disease characterised by slowness of movement, trembling (tremors) and stiffness. Currently, the best treatment for Parkinson's disease is levodopa. However, with the number of levodopa treatment years, new disabling fluctuations of movement occur. To overcome this problem, bromocriptine has been tried as an alternative drug. The review of six trials (850 participants) found that bromocriptine may be helpful in delaying such fluctuations of movement problems in patients with Parkinson's disease who can tolerate the drug.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Drugs that mimic dopamine as bromocriptine were introduced as monotherapy or in combination with LD in the hope that this approach would prevent or delay the onset of motor complications in patients with Parkinson's disease (PD). However, hitherto, the role of bromocriptine (BR) in this issue has remained controversial. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the efficacy and safety of bromocriptine (BR) monotherapy for delaying the onset of motor complications associated with levodopa (LD) therapy in patients with PD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Movement Disorders Group trials register which includes MEDLINE and EMBASE; the Cochrane Central Register of Controlled Trials (CENTRAL) <I>(The Cochrane Library)</I>; handsearched appropriate neurology journals and reference lists of reviews found by the search-strategy. We also contacted Sandoz -now Novartis- (manufacturer of BR) and contacted colleagues who had co-ordinated trials on BR.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials evaluating the efficacy of BR monotherapy for delaying the onset of motor complications compared to LD therapy alone in PD patients.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two review authors independently evaluated the methodological quality of identified trials and extracted the data from the trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Six trials with 850 participants were included. The trials were of low methodological quality and were heterogeneous so we were unable to perform a meta-analysis. The occurrence of dyskinesias in three short trials was too low to draw any conclusion. The results of the longer trials indicate a lower occurrence of dyskinesias in the BR tier. In five trials that evaluated dystonia, this motor complication occurred less frequently in the BR tier. However, for both dyskinesias and dystonia a statistically significant difference in favour of BR emerged only in the largest trial. There was a trend for wearing-off and on-off fluctuations to occur less frequently in the BR group. Although all trials evaluated participants at the impairment level, only the largest trial reported a significantly larger improvement for the LD tier during the first year of therapy. Concerning disability, which was evaluated by five trials no statistically significant differences were found. Overall, a statistically larger number of dropouts occurred in the BR group because of an inadequate therapeutic response or intolerable side effects. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Based on a qualitative review of the available data we conclude that in the treatment of early Parkinson's disease, bromocriptine may be beneficial in delaying motor complications and dyskinesias with comparable effects on impairment and disability in those patients that tolerate the drug. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Parkinson's disease (PD) is a progressive neurological disorder that produces a slowly increasing disability in movement. The main features of PD are slowness of movement (bradykinesia), trembling (tremor), increased muscle tone (rigidity), and disturbance of posture and balance. These features are caused by a depletion of the neurotransmitter dopamine due to progressive loss of the nigral neurons in the brain ( <LINK REF="REF-Bernheimer-1973" TYPE="REFERENCE">Bernheimer 1973</LINK>; <LINK REF="REF-Hornykiewicz-1966" TYPE="REFERENCE">Hornykiewicz 1966</LINK>). The general approach to the treatment of patients with PD is the administration of drugs to alleviate symptoms. This may be achieved by the restoration of dopamine by administering its precursor levodopa (LD). LD provides immediate and satisfactory control of most symptoms. However, after two to five years of stable response to LD treatment, approximately half of the patients develop motor complications (<LINK REF="REF-Marsden-1982" TYPE="REFERENCE">Marsden 1982</LINK>). Some of these motor complications are believed to be highly correlated with prolonged LD exposure (<LINK REF="REF-Lees-1989" TYPE="REFERENCE">Lees 1989</LINK>; <LINK REF="REF-Marsden-1976" TYPE="REFERENCE">Marsden 1976</LINK>; <LINK REF="REF-Shaw-1980" TYPE="REFERENCE">Shaw 1980</LINK>). The motor complications that may appear in a predictable or unpredictable relation to the timing of LD are:</P>
<UL>
<LI>Wearing-off (end-of-dose), a predictable motor complication in which the perception of loss of mobility or dexterity occurs gradually over minutes (up to an hour) as the effect of a dose of LD is waning.</LI>
<LI>On-off motor fluctuations, generally sudden (seconds to minutes) shifts between on (mobility) and off (immobility or worsening of parkinsonian features) that are not apparently related and therefore unpredictable to the timing of LD. Off-periods may last minutes to hours.</LI>
<LI>Dyskinesias, predictable abnormal involuntary movements that occur shortly after or before a single LD dose (diphasic) or in between two LD administrations (peak-dose).</LI>
<LI>Dystonia, a movement disorder characterised by sustained or intermittent muscle activity, leading to altered voluntary movement or abnormal postures. Dystonia is one of the most complex motor complications that can occur in PD. On the one hand, dystonia may manifest itself in a predictable relation with the timing of LD, and occur both during the off- and on-periods (<LINK REF="REF-Luquin-1992" TYPE="REFERENCE">Luquin 1992</LINK>). On the other hand, dystonia may also appear in untreated patients or as a result of the intrinsic advancement of PD (<LINK REF="REF-Poewe-1988" TYPE="REFERENCE">Poewe 1988</LINK>).</LI>
</UL>
<P> <BR/>Due to the aforementioned limitations of LD therapy new therapeutic approaches have been explored. In 1974 bromocriptine (BR), a dopamine agonist, was first introduced as an adjunct to conventional LD therapy in PD patients with motor fluctuations (<LINK REF="REF-Calne-1974" TYPE="REFERENCE">Calne 1974</LINK>). Dopamine agonists bypass the degenerating nigral neurons and stimulate the dopamine receptors directly (<LINK REF="REF-Corrodi-1973" TYPE="REFERENCE">Corrodi 1973</LINK>; <LINK REF="REF-Goldstein-1983" TYPE="REFERENCE">Goldstein 1983</LINK>). Following this, attention focused on the possibility of using BR monotherapy or a combination of LD and BR as a first line treatment in early PD. These treatment strategies would allow either a later start (BR monotherapy) or lower dose of LD (BR/LD combination therapy), thus potentially preventing or delaying the onset of the late complications of LD therapy.</P>
<P>The present study is a systematic review of all randomised controlled trials of BR monotherapy compared with LD monotherapy in PD. A separate review covers the effect of BR/LD combination therapy versus LD monotherapy.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the effectiveness and safety of BR monotherapy versus LD monotherapy for delaying the onset of motor complications associated with LD therapy in patients with PD.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomised controlled trials (RCTs) comparing bromocriptine with levodopa in early PD were considered for inclusion in the study. Crossover trials were eligible if the first phase of the study fulfilled these criteria.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies with PD patients suffering from idiopathic PD (diagnosed by the enrolling investigators) who had never used BR were included. The use of LD for only a short period (&lt; 6 months), peripheral decarboxylase inhibition, anticholinergic co-medication, or Amantadine was permitted.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Oral bromocriptine or levodopa.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>We used the following outcome measures:</P>
<P>1. Motor complications: the occurrence and severity of off-period related motor fluctuations (wearing-off and on-off motor fluctuations, including off-period related dystonia) and dyskinesias (chorea, including on-period related dystonia).</P>
<P>2. Symptomatic efficacy: scores of scales that evaluated:<BR/>a) Impairment<BR/>
</P>
<UL>
<LI>Webster (<LINK REF="REF-Webster-1968" TYPE="REFERENCE">Webster 1968</LINK>)</LI>
<LI>Columbia University Rating Scale (CURS; <LINK REF="REF-Yahr-1969" TYPE="REFERENCE">Yahr 1969</LINK>)</LI>
</UL>
<P>b) Disability<BR/>
</P>
<UL>
<LI>Northwestern University Disability Scale (NUDS; <LINK REF="REF-Canter-1961" TYPE="REFERENCE">Canter 1961</LINK>) </LI>
<LI>Activities of daily living scale (<LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>)</LI>
<LI>England &amp; Schwab Disability Scale (<LINK REF="REF-Schwab-1960" TYPE="REFERENCE">Schwab 1960</LINK>)</LI>
</UL>
<P>
<BR/>3. The occurrence of side effects and dropouts.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>1. The review is based on the search strategy of the Movement Disorders Group. This includes computerised searches of MEDLINE and EMBASE and handsearching of appropriate neurology journals. Relevant trials were included on the Group's specialised register of randomised controlled trials. Further details are available in the Group's module on the Cochrane Database of Systematic Reviews.</P>
<P>We also searched:<BR/>2. The Cochrane Controlled Trials Register for relevant trials. <BR/>3. The reference lists of located trials and of other bromocriptine reviews. <BR/>4. Symposia-reports and handbooks of PD.<BR/>5. Additional assistance was provided by the drug manufacturer Sandoz, now Novartis.<BR/>6. We contacted colleagues who had co-ordinated trials on BR for information on unpublished studies. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Two review authors independently reviewed the identified trials according to a two-step review process. First, the abstracts were reviewed for eligibility. Thereafter, eligible reports of studies were reviewed and data extracted independently by two reviewers. Discrepancies were registered and resolved by consensus with a third review author. </P>
<P>To determine the feasibility to perform a quantitative systematic review on BR monotherapy in PD patients, we addressed the following issues for each of the eligible studies:<BR/>
</P>
<UL>
<LI>Application of general principles of trial methodology.</LI>
<LI>Participant baseline characteristics.</LI>
<LI>Titration schedules.</LI>
<LI>Assessment procedures and outcome measures.</LI>
</UL>
<P>
<BR/>If the information on the aforementioned issues was insufficiently reported, we attempted to contact the trialists to obtain additional clarifying data.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>
<I>See</I> also table 'Characteristics of included studies'.</P>
<UL>
<LI>
<B>Number of trials identified</B>
</LI>
</UL>
<P>From 1974 to April 2007 we identified 15 RCTs that met our selection criteria. We excluded four studies that were interim analysis or preliminary reports of an included trial (<LINK REF="REF-Hely-1987" TYPE="REFERENCE">Hely 1987</LINK>; <LINK REF="REF-Hely-1989" TYPE="REFERENCE">Hely 1989</LINK>; <LINK REF="REF-Lees_x002c_Frankel-1989" TYPE="REFERENCE">Lees,Frankel 1989</LINK>; <LINK REF="REF-Parkinson_x0027_s-1993" TYPE="REFERENCE">Parkinson's 1993</LINK>) and three studies (<LINK REF="STD-Gawel-1987" TYPE="STUDY">Gawel 1987</LINK>; <LINK REF="STD-Libman-1987" TYPE="STUDY">Libman 1987</LINK>; <LINK REF="STD-Riopelle-1987" TYPE="STUDY">Riopelle 1987</LINK>) that were identical to the included trial of Riopelle (<LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>). One trial never published the final results and we could not retrieve its data (<LINK REF="STD-Wallis-1988" TYPE="STUDY">Wallis 1988</LINK>). Finally, in one trial participants were randomised to either bromocriptine or lisuride versus LD and the results were not split by bromocriptine or lisuride (<LINK REF="STD-Caraceni-2001" TYPE="STUDY">Caraceni 2001</LINK>). Of the remaining studies four evaluated BR monotherapy versus LD monotherapy and two evaluated both BR monotherapy and BR/LD combination therapy versus LD monotherapy in PD patients. These six trials randomised more than 850 participants to a BR or a LD regimen.</P>
<UL>
<LI>
<B>Participant characteristics</B>
</LI>
</UL>
<P>Not all of the included trials adequately described the included patient population. Reasons for inclusion were sometimes vague, suggesting that both patients with PD and other causes of parkinsonism were included. All studies, but Hely (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>), excluded patients, who had been previously treated with LD. Only two trials excluded explicitly patients with cognitive impairment (<LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). The mean age of the participants of each study ranged from 60.3 to 67.5 years. The mean disease duration of the trial population ranged from 11.6 months (<LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>) to 25 months (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>).</P>
<UL>
<LI>
<B>Titration schedule</B>
</LI>
</UL>
<P>All six trials introduced BR at different daily dosages ranging from 1 mg to 5 mg. The duration of the titration phase varied between four weeks (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>) and six months (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>). At the end of this period the maximum BR dosage ranged from 30 mg (<LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>) to 120 mg daily (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). Only the UK-PDRG study reported the diurnal distribution of the BR dosages at the end of the titration phase: three times daily. Dose increment varied between the trials from 1.25 mg BR every week (<LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>) to 2.5 mg BR every third day (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). Three studies introduced LD at a dosage of 50 mg LD (<LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>; <LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>). Hely started with 20 mg LD (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>), Herskovits with 125 mg LD (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>) and UK-PDRG with 150 mg LD (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). The UK-PDRG study used benserazide as the peripheral dopa decarboxylase inhibitor (DDI) in an LD/DDI-ratio of 4:1 (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). All other studies used carbidopa in addition to LD with a similar ratio, except Herskovits (10:1) (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>). Between the trials, the LD dose increment varied or remained unclear.</P>
<UL>
<LI>
<B>Assessment procedures and outcome measures</B>
</LI>
</UL>
<P>All trials evaluated the occurrence of dyskinesias. Changes in the occurrence of wearing-off were evaluated by two studies (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>) and on-off motor fluctuations by three studies (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). All studies, except Riopelle (<LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>), evaluated the occurrence of dystonia.</P>
<P>The severity of motor complications was evaluated by two included studies (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>). Impairment and disability were evaluated by all and four studies (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>), respectively. None of the included RCTs reported if impairment and disability scores referred to the on- or off-phase.</P>
<P>The principal outcome measures used in the UK-PDRG trial were mortality and assessment of disability (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>).</P>
<P>Herskovits, Olanow and Weiner evaluated the occurrence of side effects (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>; <LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>), whereas Hely only reported serious side effects (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>). In the UK-PDRG study, motor complications were evaluated as side effects (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). All studies evaluated adverse events that resulted in withdrawal of participants.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>All studies showed shortcomings of the reported information on relevant methodological issues of the trial. Therefore, we attempted to approach all trialists to obtain additional clarifying data. One trialist was deceased and therefore the requested information could not be retrieved (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>). </P>
<UL>
<LI>
<B>Trial design</B>
</LI>
</UL>
<P>All trials used a parallel LD group. Two studies randomised participants to a BR/LD combination therapy group (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>). The UK-PDRG trial (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>) compared BR monotherapy with LD plus selegiline and LD monotherapy. In Hely's trial (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>) all participants started with placebo during the first month after which they were allocated to BR or levodopa/carbidopa. Subsequently, participants were followed up regardless of whether the treatment code was broken, other drugs were added or a switch to another treatment occurred. In the BR groups of Herskovits and Olanow (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>; <LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>), 50% of the participants and five participants, respectively, required additional LD in order to maintain their improvement (mean starting time for levodopa: 16.3 months and 17 months, respectively).</P>
<UL>
<LI>
<B>Study duration </B>
</LI>
</UL>
<P>The studies had a highly variable duration: 23 weeks (<LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>) to five years (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>). Three trials are still in progress (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). Herskovits follow up period varied between 18 and 45 months (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>) and in Weiner's study this period ranged from 36 to 48 months (<LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>).</P>
<UL>
<LI>
<B>Assessors and centres</B>
</LI>
</UL>
<P>Most trials were unclear about the number of assessors that participated in the study. In Hely's study, participants were assessed at baseline and at yearly intervals by one assessor, whereas the intermediate assessments were performed by five assessors (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>). The number of participating centres was reported in three studies (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). Most studies concerned multi centre trials; the number of centres varied between four (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>) to 93 (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>).</P>
<UL>
<LI>
<B>Randomisation</B>
</LI>
</UL>
<P>Only Hely partly described the allocation procedure (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>). Additionally obtained information showed that three trials adequately randomised their participants by means of randomisation tables (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>) or by a computerised random allocation system (<LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>). For the other three studies this remained unclear.</P>
<UL>
<LI>
<B>Trial performance</B>
</LI>
</UL>
<P>Two studies were performed according to a double-blind design (<LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>). Hely's study was only double-blind during the titration phase (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>) and Olanow used a single-blind design (<LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>). For one study the blinding remained unclear (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>). The UK-PDRG study was an open trial (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>).</P>
<UL>
<LI>
<B>Sample size calculations</B>
</LI>
</UL>
<P>Only the UK-PDRG study, which included a selegiline tier, reported sample size calculations (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). The powering in this study was based on mortality data of patients with PD. </P>
<UL>
<LI>
<B>Attrition characteristics</B>
</LI>
</UL>
<P>All trials provided detailed information on the reasons for participants leaving the trials. </P>
<UL>
<LI>
<B>Data analysis</B>
</LI>
</UL>
<P>Only Hely and the UK-PDRG studies provided intention-to-treat data (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Major differences between studies concerning the baseline characteristics, the BR titration phase, and the outcomes measured were found. Considerable variability was found with respect to the duration of the trials and the individual follow up of participants in some of the trials. The 15 participants in Weiner's study had a variable follow up between 36 to 48 months (<LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>). Hence, for this study the data was evaluated for the first three years only. Data of the participants' assessments was available for Weiner's trial (<LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>) and at yearly intervals for Hely's trial (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>). For the remaining four trials, data was only available at baseline and at the end of the trial. </P>
<P>Due to the aforementioned methodological problems and incomparability of studies we could not pool the results from the different trials. Available data of individual studies was re-analysed with Cochrane MetaView software and trials were evaluated for potential sources of methodological heterogeneity (differences in study design) and clinical heterogeneity (differences between studies in participants characteristics, interventions or outcome measures).</P>
<UL>
<LI>
<B>Occurrence of motor complications</B>
</LI>
</UL>
<P>Dyskinesias - (reported by six trials). In two trials (&lt;18 months) dyskinesias did not occur (<LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>; <LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>) or occurred in only one participant in both groups (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>). Re-analysis of three longer trials (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>) indicate a lower occurrence of dyskinesia in the BR tier, only statistically significant in the largest trial after three years of treatment (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>).</P>
<P>Dystonia - (reported by five trials). Dystonia was reported in four studies less frequently in the BR group (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>), only statistically significant in the UK-PDRG study. In the Herskovits study, dystonia occurred in two participants after an unspecified period of LD treatment (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>). </P>
<P>Wearing-off - (reported by two trials). In Hely's study, wearing-off occurred in three participants (N = 21) on BR and 1 participant (N = 60) on LD after two years follow up (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>). At four and five years wearing off was found significantly more often in the LD group. In the Olanow study, one participant developed mild wearing-off after six months of LD treatment (<LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>). </P>
<P>On-off - (reported by 3 trials). After three years the UK-PDRG study reported a statistically significant larger number of participants with on-off fluctuations in patients using LD (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). On-off fluctuations were reported in one participant after five years of LD treatment in Hely's trial (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>) and did not occur in Olanow's study (<LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>). </P>
<UL>
<LI>
<B>Severity of motor complications (reported by two trials)</B>
</LI>
</UL>
<P>Hely, using an item on dyskinesias from the Unified Parkinson's Disease Rating Scale (<LINK REF="REF-UPDRS-1987" TYPE="REFERENCE">UPDRS 1987</LINK>) reported that the severity of dyskinesias remained mild with no major difference between both treatment regimens (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>). Wearing-off was graded as mild in both groups (scale: mild-moderate-severe). Weiner, using a 0 to 4 scale to score the severity of all motor complications, found no significant difference between both groups (<LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>). </P>
<UL>
<LI>
<B>Impairment (reported by six trials)</B>
</LI>
</UL>
<P>In the UK-PDRG study, the sum score of the Webster rating showed only a statistically significant difference in favour of the LD monotherapy group during the first year of follow up (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). Comparisons at three years were not reported. Hely and Weiner used a modified Columbia Rating Scale and found no significant difference in the mean change from baseline between both groups (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>). Olanow applied a self-constructed composite score of impairment and disability scales (modified England-Schwab Disability Scale, a modified Columbia Scale and the Hoehn and Yahr stage) (<LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>). This composite score showed a statistically significant improvement over baseline, but no difference between groups. Riopelle, who used the Columbia University Scale, reported similar results (<LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>). Herskovits used a Webster scale and found no significant differences between both groups at the final assessment (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>).</P>
<UL>
<LI>
<B>Disability (reported by four trials)</B>
</LI>
</UL>
<P>Riopelle (North-western University Disability Scale: NUDS) (<LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>), Hely (modified NUDS) (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>), and Weiner (Activities of Daily Living scale) (<LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>) reported no significant difference between both groups with respect to the change from baseline. In the UK-PDRG study no formal results (NUDS) were reported but in the published report it is mentioned that the NUDS score followed a similar trend as the Webster scale (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>).</P>
<UL>
<LI>
<B>Side effects</B>
</LI>
</UL>
<P>Olanow reported nausea in 12 participants (N = 24) on LD and in seven participants (N = 23) on BR (<LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>). In Weiner's study only one participant in each group experienced hallucinations, other side effects being reported as uncommon (<LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>). Herskovits reported more nausea and hallucinations in the LD group (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>). Hely, UK-PDRG and Riopelle only reported side effects that resulted in withdrawal (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). </P>
<UL>
<LI>
<B>Number of withdrawals</B>
</LI>
</UL>
<P>In Weiner's study one participant stopped BR therapy because of loss of efficacy (at 45 months) and one participant on LD dropped out because of elevation of liver enzymes (at 15 months) (<LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>). Herskovits reported three dropouts; one in each treatment group due to gastric intolerance and one on BR due to allergic nodular vasculitis (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>). During the dose-titration phase of the Riopelle study, BR treated participants dropped out because of nausea (n = 3) and confusion (n = 1) (<LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>). No withdrawals occurred in the LD group. In Olanow's trial, one BR participant was lost to follow up after nine months (<LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>). In the LD group two participants withdrew for no apparent reason after six and nine months, one participant was lost to follow up, and one participant died from amyotrophic lateral sclerosis (ALS). In the UK-PDRG study, 181 participants (N = 263) on BR and 80 participants (N = 249) on LD were withdrawn at three years follow up (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). The main reason for withdrawal in the BR arm was adverse events, lack of response or deterioration. In the LD group, the most common reason was protocol violation mostly due to the introduction of selegiline.</P>
<P>Hely's intention-to-treat design resulted in a complex flowchart of the participants during the five years of follow up (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>). At five years follow up only two participants were still using BR monotherapy with anticholinergics. Most other participants were lost in follow up (n = 11) or switched to LD or other therapies (n = 40). One participant developed retroperitoneal fibrosis after three years of BR, and two participants developed pulmonary fibrosis after 2.5 and five years of BR. In the LD group, 36 participants were able to remain on the original treatment and 11 definite dropouts occurred. In most of the participants that were unable to remain on LD, bromocriptine or anticholinergics were added. Nine of the 62 participants from the BR group and seven of the 64 participants from the LD group had died at five years follow up from pneumonia or due to cardiovascular causes.</P>
<UL>
<LI>
<B>Mean achieved drug dose</B>
</LI>
</UL>
<P>The mean daily doses of LD (without carbidopa or benserazide) after one year's treatment ranged from 195 mg (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>) to 336 mg (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). At final evaluations the mean dose varied from 376 mg (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>/ five years) to 635 mg (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>/ four years). The mean daily doses of BR varied after one year from 18 mg (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>) to 36 mg (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). However, in the UK-PDRG study the BR dose ranged from 7.5 to 120 mg per day (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This systematic review included six eligible trials that compared BR monotherapy with LD monotherapy (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>; <LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>; <LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>). Three excluded studies were multiple publications of the same trial (<LINK REF="STD-Gawel-1987" TYPE="STUDY">Gawel 1987</LINK>; <LINK REF="STD-Libman-1987" TYPE="STUDY">Libman 1987</LINK>; <LINK REF="STD-Riopelle-1987" TYPE="STUDY">Riopelle 1987</LINK>). Additionally, we excluded two interim reports (<LINK REF="REF-Hely-1987" TYPE="REFERENCE">Hely 1987</LINK>; <LINK REF="REF-Lees_x002c_Frankel-1989" TYPE="REFERENCE">Lees,Frankel 1989</LINK>) and one study whose final data were not published and could not be retrieved (<LINK REF="STD-Wallis-1988" TYPE="STUDY">Wallis 1988</LINK>). </P>
<P>All trials had problems regarding general and PD-related trial methodology. Particularly worrisome is the lack of available information on the type and concealment of the randomisation procedure in the initially published reports. Information provided later on revealed that this essential element of trial methodology was carried out adequately in only three trials (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>). Except for two trials (<LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>), all were performed in an open manner. Only two trials analysed their data according to an intention-to-treat principle (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>).</P>
<P>The mean duration of trials showed a wide range between five months to five years, with some of the trials still ongoing. In view of the aim of BR monotherapy in delaying the onset of motor complications, short trials (&lt; 1 year) are of relative value. </P>
<P>Relevant differences between the trials emerged concerning mean age of the participants (60.3 to 67.5 years). Some studies included the results of participants that eventually turned out to suffer from PD plus syndromes in their final data analysis so as to reflect clinical practice whereas others did not. Major differences regarding the rate by which BR was introduced in the titration phase as well as the achieved mean daily dose of LD (376 to 635 mg) and BR (18 to 36 mg) were found. Such differences are likely to influence the performance of trials, the occurrence of adverse events and consequently the dropout rate. Moreover, the included studies used a wide range of methods to assess the occurrence of the various aspects of motor complications and applied different impairment and disability scales that lacked a solid clinimetric basis. Additionally, none of the included trials reported whether scores on impairment and disability level referred to the on- or off-phase.</P>
<P>Due to these differences concerning methodology and content we could not pool the data from the different trials in an attempt to perform a meta-analysis. Therefore, we re-analysed the available data and evaluated possible sources of methodological heterogeneity (differences in study design) and clinical heterogeneity (differences between studies in participants' characteristics, interventions or outcome measures) between the studies. </P>
<P>Three short trials reported no or a very low occurrence of dyskinesias (<LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>; <LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>; <LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>). The results of the more relevant longer trials (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; ; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>) indicate a lower occurrence of dyskinesias in the BR tier, only statistically significant in the largest UK-PDRG trial (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). In five trials that evaluated dystonia, this motor complication occurred more frequent in the LD tier; the difference being statistically significant only in the UK-PDRG trial (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). </P>
<P>During the LD treatment of patients with PD, wearing off is the first and most frequent off-related motor complication to occur. Nevertheless, surprisingly only two trials evaluated this motor complication (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>). In the short trial of Olanow only one participant developed wearing off after six months of LD treatment (<LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>). Hely found a significantly larger number of participants suffering wearing off in the LD tier at four and five year's follow up (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>). On-off fluctuations, reported by three trials (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>), occurred in only one participant after five years LD treatment in the Hely trial (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>), suggesting that the trial design allowing low LD dosages or additional therapy prevented the occurrence of this motor complication. However, in the UK-PDRG study 82 participants (N = 263) in the LD group and only 13 participants (N = 249) in the BR group developed on-off fluctuations, the difference being statistically significant (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). </P>
<P>Although all trials evaluated participants at the impairment level, only one trial reported a significantly larger improvement for the LD tier during the first year of therapy (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). Of the other five trials that evaluated disability, none reported a statistically significant difference between the treatment groups (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-Herskovits-1988" TYPE="STUDY">Herskovits 1988</LINK>; <LINK REF="STD-Olanow-1987" TYPE="STUDY">Olanow 1987</LINK>; <LINK REF="STD-Riopelle-1988" TYPE="STUDY">Riopelle 1988</LINK>; <LINK REF="STD-Weiner-1993" TYPE="STUDY">Weiner 1993</LINK>).</P>
<P>For the three studies that reported the incidence of side effects, we found no differences between both tiers. The trial design in Hely in which participants were allowed to switch to other therapies, was probably responsible for their relatively low definite dropout rates (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>). After five years only two participants, of the originally 62 randomised in this trial, were still using BR with anticholinergics. Overall, a statistically larger number of dropouts occurred in the BR group because of an inadequate therapeutic response or because of intolerable side effects.</P>
<P>Taken together this review identified important sources of heterogeneity between the six eligible trials that may explain the different results. <BR/>
</P>
<UL>
<LI>First, the detection of possible differences between studies, if any, is confounded because the majority of the studies were inadequately powered to detect such differences between the two treatment tiers. Only the UK-PDRG study reported sample size calculations (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>).</LI>
<LI>Second, the limited duration of many trials resulted in a low occurrence of motor complications. For several studies a trend in favour of BR was found concerning the occurrence of motor fluctuations. Only the UK-PDRG trial detected statistically significant differences in favour of BR (<LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>). One may argue that the UK-PDRG trial was only powered to detect a 30% reduction of mortality. Nevertheless, the sample size of this trial is likely to be sufficient for other purposes as well. </LI>
<LI>Third, important differences concerning the trial design were found which might explain differences in the occurrence of motor complications between the UK-PDRG and Hely trials (<LINK REF="STD-Hely-1994" TYPE="STUDY">Hely 1994</LINK>; <LINK REF="STD-UK_x002d_PDRG-1993" TYPE="STUDY">UK-PDRG 1993</LINK>).</LI>
</UL>
<P>
<BR/>Numerous reviews discussing the role of BR in the management of motor complications in PD have appeared, but this issue remains controversial (<LINK REF="REF-Ahlsog-1994" TYPE="REFERENCE">Ahlsog 1994</LINK>; <LINK REF="REF-Factor-1993" TYPE="REFERENCE">Factor 1993</LINK>; <LINK REF="REF-Goetz-1990" TYPE="REFERENCE">Goetz 1990</LINK>; <LINK REF="REF-Watts-1997" TYPE="REFERENCE">Watts 1997</LINK>). This systematic review identified important sources of methodological as well as clinical heterogeneity including inadequate powering of the studies, clinically relevant differences in trial duration, outcomes and trial design. These important issues may explain the different results and why many findings failed to reach a statistically significant level. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The treatment of PD, lacking a cure, aims to limit the gradually increasing amount of disability. In this regard, the most effective strategy is the treatment with LD, which improves some of the PD features. However, for every year of LD treatment the number of patients that will develop motor complications increases. These complications contribute to an additional disease burden and become a source of increased medical care. </P>
<P>From 1974 to January 1999, six RCTs were identified that evaluated the efficacy of BR monotherapy for delaying the onset of motor complications associated with LD therapy in patients with PD. Methodological problems and incomparability of studies precluded the pooling of data in an attempt to perform meta-analysis. Nevertheless, re-analysis of available data suggest that BR is beneficial in delaying motor complications in those patients who tolerate and respond to the drug with comparable effects on impairment and disability.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>This review emphasises methodological shortcomings in the six BR trials. The issues arising from this review have a significant bearing on the conduct of future dopamine agonist trials in this type of patient.</P>
<P>There is a clear requirement to apply a uniform general and PD-related trial methodology. With respect to the former our findings underscore the application of the guidelines suggested by the Consolidated Standards of Reporting Trials (CONSORT, <LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>) and in our previous review on BR in late PD.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Dr. M. Hely, L. Hendricks and N. Liyanaga (Sandoz, now Novartis), Dr. A.J. Lees, Dr. R. J. Riopelle, Dr. W.J. Weiner.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>&lt;None&gt;<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>JJ Van Hilten contributed to the design of the protocol and was involved in data extraction, analysis and interpretation for the review<BR/>Claudia Ramaker contributed to the design of the protocol and was involved in data extraction, analysis and interpretation for the review<BR/>Rebecca Stowe was involved in data extraction, analysis and interpretation for the review<BR/>Natalie Ives was involved in data extraction, analysis and interpretation for the review</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-Hely-1994" NAME="Hely 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hely MA, Morris JG, Rail D, O'Sullivan DJ, Williamson PM, Genge S, et al</AU>
<TI>The Sydney multicentre study of Parkinson's disease: The first 18 months</TI>
<SO>The Medical Journal of Australia</SO>
<YR>1987</YR>
<VL>146</VL>
<PG>195-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hely MA, Morris JG, Rail D, Reid WG, O'Sullivan DJ, Willaimson PM et al</AU>
<TI>The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1989</YR>
<VL>52</VL>
<PG>324-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Hely MA, Morris JGL, Reid WGJ, O'sullivan DJ, Williamson PM, Rail D, Broe GA, Margrie S. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994; 57: 903-910.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hely MA, Morris JGL, Reid WGJ, O'Sullivan DJ, Williamson PM, Rail D, et al</AU>
<TI>The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing with low dose bromocriptine with low dose levodopa-carbidopa</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1994</YR>
<VL>57</VL>
<PG>903-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herskovits-1988" NAME="Herskovits 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Herskovits E, Yorio A, Leston J. Long term bromocriptine treatment in de novo parkinsonian patients. Medicina (B Aires) 1988; 48(4): 345-350.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herskovits E, Yorio A, Leston J</AU>
<TI>Long term bromocriptine treatment in de novo Parkinsonian patients</TI>
<SO>Medicina (B Aires)</SO>
<YR>1988</YR>
<VL>48</VL>
<NO>4</NO>
<PG>345-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olanow-1987" NAME="Olanow 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="BOOK">
<AU>Olanow CW, Alberts MJ, Stajich J, Burch G</AU>
<TI>A randomized blinded study of low-dose bromocriptine versus low-dose carbidopa/levodopa in untreated Parkinson's patients</TI>
<SO>Recent developments in Parkinson's disease</SO>
<YR>1987</YR>
<VL>II</VL>
<PG>201-208</PG>
<ED>Fahn S, Marsden D, Calne D, Goldstein M</ED>
<PB>Macmillan Healthcare</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Riopelle-1988" NAME="Riopelle 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Riopelle RJ, Gawel MJ, Libman I, King DB, McLean DR, Paulseth R, Raphy B, Bouchard S. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short term results. Eur Neurol 1988; 28 Suppl 1: 11-14.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riopelle RJ, Gawel MJ, Libman I, King DB, McLean DR, Paulseth R, et al</AU>
<TI>A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short term results</TI>
<SO>European Neurology</SO>
<YR>1988</YR>
<VL>28 Suppl 1</VL>
<PG>11-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-UK_x002d_PDRG-1993" NAME="UK-PDRG 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lees AJ, Frankel J, Eatough V, Stern GM</AU>
<TI>New approaches in the use of selegiline for the treatment of Parkinson's disease</TI>
<SO>Acta Neurologica Scandinavica. Supplementum</SO>
<YR>1989</YR>
<VL>126</VL>
<PG>139-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Lees AJ: Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom [see comments]. BMJ 1995;311:1602-1607.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease</AU>
<TI>Parkinson's Disease Research Group of the United Kingdom</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>1602-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegine, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993; 307: 469-472.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parkinson's Disease Research Group in the United Kingdom</AU>
<TI>Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>307</VL>
<PG>469-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Weiner-1993" NAME="Weiner 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Weiner WJ, Factor SA, Sanchez-Ramos JR, Singer C, Sheldon RN, Cornelius L, Ingenito A. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993 Jan; 43(1): 21-27.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiner WJ, Factor SA, Sanchez-Ramos JR, Singer C, Sheldon RN, Cornelius L, et al</AU>
<TI>Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>1</NO>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Caraceni-2001" NAME="Caraceni 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Caraceni T, Musicco M</AU>
<TI>Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicentre study</TI>
<SO>Parkinsonism and Related Disorders</SO>
<YR>2001</YR>
<VL>107</VL>
<PG>107-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gawel-1987" NAME="Gawel 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Gawel M, Riopelle R, Libman I, Bouchard S: Bromocriptine in the treatment of Parkinson's disease: a double- blind study against L-dopa/carbidopa. Adv Neurol 1987;45:535-538.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gawel M, Riopelle R, Libman I, Bouchard S</AU>
<TI>Bromocriptine in the treatment of Parkinson's disease: a double- blind study against L-dopa/carbidopa</TI>
<SO>Advances in Neurology</SO>
<YR>1987</YR>
<VL>45</VL>
<PG>535-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Libman-1987" NAME="Libman 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Libman I, Gawel MJ, Riopelle RJ, Bouchard S: A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of &amp;quot;de novo&amp;quot; Parkinson's disease patients. Can J Neurol Sci 1987;14:576-580.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Libman I, Gawel MJ, Riopelle RJ, Bouchard S</AU>
<TI>A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients</TI>
<SO>The Canadian Journal of Neurological Sciences</SO>
<YR>1987</YR>
<VL>14</VL>
<PG>576-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riopelle-1987" NAME="Riopelle 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Riopelle RJ: Bromocriptine and the clinical spectrum of Parkinson's disease. Can J Neurol Sci 1987;14:Suppl):455-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riopelle RJ</AU>
<TI>Bromocriptine and the clinical spectrum of Parkinson's disease</TI>
<SO>The Canadian Journal of Neurological Sciences</SO>
<YR>1987</YR>
<VL>14(Suppl)</VL>
<PG>S455-S9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallis-1988" NAME="Wallis 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Wallis WE: A progress report on the New Zealand Multicentre Parkinson's disease trial. A comparison of low-dose treatment with bromocriptine or L-dopa. Eur Neurol 1988;28:Suppl 1:9-10.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallis WE. A progress report on the New Zealand Multicentre Parkinson's disease trial</AU>
<TI>A comparison of low-dose treatment with bromocriptine or L-dopa</TI>
<SO>European Neurology</SO>
<YR>1988</YR>
<VL>28(Suppl 1)</VL>
<PG>S9-S10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Ahlsog-1994" NAME="Ahlsog 1994" NOTES="&lt;p&gt;Ahlskog JE. Treatment of Parkinson's disease. From theory to practice. Postgrad Med 1994; 95:52-54.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ahlskog JE</AU>
<TI>Treatment of Parkinson's disease. From theory to practice</TI>
<SO>Postgraduate Medicine</SO>
<YR>1994</YR>
<VL>95</VL>
<PG>52-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="652"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bernheimer-1973" NAME="Bernheimer 1973" NOTES="&lt;p&gt;74081469 JOURNAL ARTICLE 0022-510X M JBJ 197405 PMID- 0004272516&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F</AU>
<TI>Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>1973</YR>
<VL>20</VL>
<NO>4</NO>
<PG>415-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="622"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Calne-1974" NAME="Calne 1974" NOTES="&lt;p&gt;treatment - 76124813 JOURNAL ARTICLE 0140-6736 A M L0S 197606 PMID- 0004143315&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Calne DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK</AU>
<TI>Treatment of parkinsonism with bromocriptine</TI>
<SO>Lancet</SO>
<YR>1974</YR>
<VL>2</VL>
<NO>7893</NO>
<PG>1355-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="621"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Canter-1961" NAME="Canter 1961" TYPE="JOURNAL_ARTICLE">
<AU>Canter CJ, de la Torre R, Mier M</AU>
<TI>A method of evaluating disability in patients with Parkinson's disease</TI>
<SO>The Journal of Nervous and Mental Disease</SO>
<YR>1961</YR>
<VL>133</VL>
<PG>143-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corrodi-1973" NAME="Corrodi 1973" NOTES="&lt;p&gt;73224417 JOURNAL ARTICLE 0022-3573 M JNR 197311 PMID- 0004146398&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Corrodi H, Fuxe K, Hokfelt T, Lidbrink P, Ungerstedt U</AU>
<TI>Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons</TI>
<SO>The Journal of Pharmacy and Pharmacology</SO>
<YR>1973</YR>
<VL>25</VL>
<NO>5</NO>
<PG>409-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="623"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Rijk-1995" NAME="de Rijk 1995" NOTES="&lt;p&gt;96109134 JOURNAL ARTICLE 0028-3878 A M NZ0 199612 We assessed the prevalence of Parkinson's disease (PD) in a general elderly population in the Netherlands. The study formed part of the Rotterdam Study, a population-based door-to-door study, and included 6,969 persons 55 years of age or older living in a suburb of Rotterdam, the Netherlands. All participants were examined, and those who either had at least one possible cardinal sign of parkinsonism at the neurologic screening, reported that they had PD, or were taking antiparkinsonian drugs were invited for further evaluation. The prevalence of PD in this population was 1.4% (1.2% for men, 1.5% for women). Prevalence increased with age, and prevalence figures were 0.3% for those aged 55 to 64 years, 1.0% for those 65 to 74, 3.1% for those 75 to 84, and 4.3% for those 85 to 94. The corresponding age-specific figures for men were 0.4%, 1.2%, 2.7%, and 3.0%, and for women, 0.2%, 0.8%, 3.4%, and 4.8%. Among 95- to 99-year-old women the prevalence was 5.0%. Twelve percent of the subjects with PD were detected through the screening and had not been diagnosed previously&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, et al</AU>
<TI>Prevalence of Parkinson's disease in the elderly: the Rotterdam Study</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45</VL>
<NO>12</NO>
<PG>2143-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="639"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" NOTES="&lt;p&gt;95195448 JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL 0959-8138 A M X BMJ 199506 OBJECTIVE--To examine the sensitivity and precision of Medline searching for randomised clinical trials. DESIGN--Comparison of results of Medline searches to a &amp;quot;gold standard&amp;quot; of known randomised clinical trials in ophthalmology published in 1988; systematic review (meta- analysis) of results of similar, but separate, studies from many fields of medicine. POPULATIONS-- Randomised clinical trials published in 1988 in journals indexed in Medline, and those not indexed in Medline and identified by hand search, comprised the gold standard. Gold standards for the other studies combined in the meta-analysis were based on: randomised clinical trials published in any journal, whether indexed in Medline or not; those published in any journal indexed in Medline; or those published in a selected group of journals indexed in Medline. MAIN OUTCOME MEASURE--Sensitivity (proportion of the total number of known randomised clinical trials identified by the search) and precision (proportion of publications retrieved by Medline that were actually randomised clinical trials) were calculated for each study and combined to obtain weighted means. Searches producing the &amp;quot;best&amp;quot; sensitivity were used for sensitivity and precision estimates when multiple searches were performed. RESULTS--The sensitivity of searching for ophthalmology randomised clinical trials published in 1988 was 82%, when the gold standard was for any journal, 87% for any journal indexed in Medline, and 88% for selected journals indexed in Medline. Weighted means for sensitivity across all studies were 51%, 77%, and 63%, respectively. The weighted mean for precision was 8% (median 32.5%). Most searchers seemed not to use freetext subject terms and truncation of those terms. CONCLUSION-- Although the indexing terms available for searching Medline for randomised clinical trials have improved, sensitivity still remains unsatisfactory. A mechanism is needed to &amp;quot;'register&amp;quot; known trials, preferably by retrospective tagging of Medline entries, and incorporating trials published before 1966 and in journals not indexed by Medline into the system&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="624"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Factor-1993" NAME="Factor 1993" NOTES="&lt;p&gt;93341510 0 (Levodopa) 25614-03-3 (Bromocriptine) JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL 0885-3185 M NIA 199311 The use of early combination therapy with bromocriptine (Br) and levodopa (LD) in Parkinson's disease is controversial. It has been suggested that treatment with this regimen would prevent or delay the onset of motor fluctuations and dyskinesia. Thus, some have recommended it as a standard of care. This recommendation is based on the theory that LD may accelerate the progression of PD and clinical experience using Br monotherapy in early Parkinson's disease, which suggested that Br causes fewer late complications. This article reviews these arguments and shows that the theories are unproven. A single, uncontrolled trial is often referred to as evidence for efficacy of early combination therapy. We critically review this and five other studies which have evaluated the treatment strategy. We show that the literature is often misleading and that these trials do not support the efficacy of early combination therapy. We conclude that there is no justifiable reason to use a combination of Br and LD in early parkinsonian patients&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Factor SA, Weiner WJ</AU>
<TI>Early combination therapy with bromocriptine and levodopa in Parkinson's disease</TI>
<SO>Movement Disorders</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>3</NO>
<PG>257-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="158"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goetz-1990" NAME="Goetz 1990" NOTES="&lt;p&gt;91015804 0 (Dopamine Agents) 25614-03-3 (Bromocriptine) 66104-22-1 (Pergolide) JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL 0028-3878 A M NZ0 199101&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Goetz CG</AU>
<TI>Dopaminergic agonists in the treatment of Parkinson's disease</TI>
<SO>Neurology</SO>
<YR>1990</YR>
<VL>40</VL>
<NO>10:Suppl 3</NO>
<PG>50-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="709"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1983" NAME="Goldstein 1983" NOTES="&lt;p&gt;83267519 0 (Adrenergic alpha-Agonists) 0 (Ergolines) 51-41-2 (Norepinephrine) 51-61-6 (Dopamine) 64795-35-3 (CQ 32085) 66104-22-1 (Pergolide) 85760-74-3 (Quinpirole) JOURNAL ARTICLE 0303-6995 M JAK 198311 The antiparkinsonian activity of several dopamine agonists was investigated in an animal model and clinically in parkinsonian patients. The semisynthetic ergoline, pergolide, the partial ergoline, LY 141865 and the 8-alpha-aminoergoline, CU 32-085 were found to be effective antitremor agents in monkeys with ventromedial tegmental lesions. The administration of pergolide or LY 141865 results in a relief of tremor with a concomitant occurrence of severe abnormal involuntary movements, while the administration of CU 32-085 results in a relief of tremor with the occurrence of only minor abnormal involuntary movements. Clinical studies have revealed that pergolide is an effective drug in patients with advanced Parkinson's disease, and it reduces the &amp;quot;on-off&amp;quot; phenomena. The possible regulation of dopamine neurotransmission by the norepinephrine neuronal systems was reviewed. Preliminary data suggest that clonidine may interact with presynaptic dopamine receptors. PMID- 0006135744&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein M, Engel J, Lieberman A, Regev I, Bystritsky A, Mino S</AU>
<TI>Therapeutic potentials of centrally acting dopamine and alpha 2- adrenoreceptor agonists</TI>
<SO>Journal of Neural Transmission. Supplementum</SO>
<YR>1983</YR>
<VL>18</VL>
<PG>257-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="627"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hely-1987" NAME="Hely 1987" TYPE="JOURNAL_ARTICLE">
<AU>Hely MA, Morris JG, Rail D, O'Sullivan DJ, Williamson PM, Genge S, et al</AU>
<TI>The Sydney multicentre study of Parkinson's disease: The first 18 months</TI>
<SO>The Medical Journal of Australia</SO>
<YR>1987</YR>
<VL>146</VL>
<PG>195-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hely-1989" NAME="Hely 1989" TYPE="JOURNAL_ARTICLE">
<AU>Hely MA, Morris JG, Rail D, Reid WG, O'Sullivan DJ, Williamson PM, et al</AU>
<TI>The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1989</YR>
<VL>52</VL>
<PG>324-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoehn-1967" NAME="Hoehn 1967" NOTES="&lt;p&gt;67139030 JOURNAL ARTICLE 0028-3878 M NZ0 196708 PMID- 0006067254&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hoehn MM, Yahr MD</AU>
<TI>Parkinsonism: onset, progression and mortality</TI>
<SO>Neurology</SO>
<YR>1967</YR>
<VL>17</VL>
<NO>5</NO>
<PG>427-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="632"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hornykiewicz-1966" NAME="Hornykiewicz 1966" NOTES="&lt;p&gt;66154279 JOURNAL ARTICLE REVIEW 0031-6997 M P40 196611&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hornykiewicz O</AU>
<TI>Dopamine (3-hydroxytyramine) and brain function</TI>
<SO>Pharmacological Reviews</SO>
<YR>1966</YR>
<VL>18</VL>
<NO>2</NO>
<PG>925-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="633"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lees-1989" NAME="Lees 1989" NOTES="&lt;p&gt;89328447 0 (Levodopa) JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL 0022-3050 M JBB 198911 The on-off phenomenon is an almost invariable consequence of sustained levodopa treatment in patients with Parkinson's disease. Phases of immobility and incapacity associated with depression alternate with jubilant thaws. Both pharmacokinetic and pharmacodynamic factors are involved in its pathogenesis, but evidence is presented to indicate that the importance of levodopa handling has been underestimated and that progressive reduction in the storage capacity of surviving nigrostriatal dopamine terminals is not a critical factor. Re- distribution of levodopa dosage which may mean smaller, more frequent doses, or larger less frequent increments, may be helpful in controlling oscillations in some patients. Dietary protein restriction, the use of selegiline hydrochloride and bromocriptine may also temporarily improve motor fluctuations. New approaches to management include the use of subcutaneous apomorphine, controlled-release preparations of levodopa with a peripheral dopa decarboxylase inhibitor and the continuous intra-duodenal administration of levodopa&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Lees AJ</AU>
<TI>The on-off phenomenon</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1989</YR>
<VL>Suppl</VL>
<PG>29-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="634"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lees_x002c_Frankel-1989" NAME="Lees,Frankel 1989" TYPE="JOURNAL_ARTICLE">
<AU>Lees AJ, Frankel J, Eatough V, Stern GM</AU>
<TI>New approaches in the use of selegiline for the treatment of Parkinson's disease</TI>
<SO>Acta Neurologica Scandinavica. Supplementum</SO>
<YR>1989</YR>
<VL>126</VL>
<PG>139-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Luquin-1992" NAME="Luquin 1992" NOTES="&lt;p&gt;92261639 0 (Dopamine Agents) 0 (Levodopa) 0 (Receptors, Dopamine) 15676-16-1 (Sulpiride) 18016-80-3 (Lisuride) 50-53-3 (Chlorpromazine) 58-00-4 (Apomorphine) JOURNAL ARTICLE 0885-3185 M NIA 199208 Levodopa-induced dyskinesias (LID) in Parkinson's disease (PD) may be classified into three main categories: &amp;quot;On&amp;quot; dyskinesias, diphasic dyskinesias (DD), and &amp;quot;off&amp;quot; periods. The study of 168 parkinsonian patients showed that about half (n = 84) showed one pattern of LID only. A combination of two was present in 68, and 16 had the three presentation patterns. A fairly good correlation between type of dyskinesia and presentation pattern was established. Chorea, myoclonus, and dystonic movements occurred during the &amp;quot;on&amp;quot; period. Dystonic postures, particularly affecting the feet, were mainly present in the &amp;quot;off&amp;quot; period, but a few patients had a diphasic presentation. Repetitive stereotyped movements of the lower limbs always corresponded to DD. Acute pharmacological tests using dopamine agonists (subcutaneous apomorphine 3-8 mg; intravenous lisuride 0.1-0.15 mg) and dopamine antagonists (intravenous sulpiride 200-400 mg and intravenous chlorpromazine 25 mg) were performed in 40 patients. Dopamine agonists enhanced &amp;quot;on&amp;quot; dyskinesias and markedly reduced or abolished &amp;quot;off&amp;quot; period dystonia and DD. Dopamine antagonists reduced all types of LID but usually aggravated parkinsonism. These clinical and pharmacological results indicate that LID in PD are a heterogeneous phenomenon difficult to explain on the basis of a single pathophysiological mechanism&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA</AU>
<TI>Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification</TI>
<SO>Movement Disorders</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>2</NO>
<PG>117-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="641"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marsden-1976" NAME="Marsden 1976" NOTES="&lt;p&gt;76124463 JOURNAL ARTICLE 0140-6736 A M L0S 197606 Fluctuations in performance in patients with Parkinson's disease on chronic levodopa therapy (the &amp;quot;on-off&amp;quot; effect) are due to several factors. The increasing severity during treatment of early morning akinesia, &amp;quot;freezing&amp;quot; episodes, and end-of-dose deterioration are probably due to progression of the underlying disease. Peak-dose dyskinesia and peak-dose akinesia are due to levodopa over dosage. &amp;quot;Yo- yo-ing&amp;quot;, which is the severest form of such fluctuation in mobility and dyskinesias, may represent the sum of these disorders. PMID- 0000055599&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Marsden CD, Parkes JD</AU>
<TI>"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>1</VL>
<NO>7954</NO>
<PG>292-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="618"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marsden-1982" NAME="Marsden 1982" TYPE="BOOK_SECTION">
<AU>Marsden CD, Parkes JD, Quinn N</AU>
<TI>Fluctuations of disability in Parkinson's disease: clinical aspects</TI>
<SO>Movement Disorders</SO>
<YR>1982</YR>
<ED>Marsden CD, Fahn S</ED>
<PB>Butterworths Scientific</PB>
<CY>London</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="619"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parkinson_x0027_s-1993" NAME="Parkinson's 1993" NOTES="&lt;p&gt;Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegine, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993; 307: 469-472.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Parkinson's Disease Research Group in the United Kingdom</AU>
<TI>Comparisons of therapeutic effects of levodopa, levodopa and selegine, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>307</VL>
<PG>469-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poewe-1988" NAME="Poewe 1988" NOTES="&lt;p&gt;88148921 0 (Levodopa) JOURNAL ARTICLE 0364-5134 M 6AE 198806 We studied the features of dystonia in 9 patients with untreated idiopathic Parkinson's disease and in 56 patients on sustained treatment with L-dopa. Dystonia was seen as an initial symptom in patients with both early- and late-onset Parkinson's disease and included action dystonia of the limbs and cranial dystonia. Although the coexistence of parkinsonism and dystonia suggests a common pathophysiology, antiparkinsonian drugs did not consistently influence dystonic spasms. L-dopa-induced dystonia was seen as an off-period, biphasic, or peak-dose phenomenon. Each type showed a distinctive pattern of localization of dystonic spasms, possibly reflecting neurochemical aspects of basal ganglia somatotopy. Neuropharmacological studies performed in 12 patients suggest that off-period dystonia is genuinely induced by L-dopa and best relieved by antiparkinsonian agents&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Poewe WH, Lees AJ, Stern GM</AU>
<TI>Dystonia in Parkinson's disease: clinical and pharmacological features</TI>
<SO>Annals of Neurology</SO>
<YR>1988</YR>
<VL>23</VL>
<NO>1</NO>
<PG>73-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="636"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schwab-1960" NAME="Schwab 1960" TYPE="JOURNAL_ARTICLE">
<AU>Schwab RS</AU>
<TI>Progression and prognosis in Parkinson's disease</TI>
<SO>The Journal of Nervous and Mental Disease</SO>
<YR>1960</YR>
<VL>130</VL>
<PG>556-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shaw-1980" NAME="Shaw 1980" NOTES="&lt;p&gt;81125065 0 (Levodopa) JOURNAL ARTICLE 0033-5622 M QKZ 198106 The progress of 178 patients with Parkinson's disease who began treatment with levodopa between November 1969 and December 1972 is reviewed after six years. One hundred and twenty-five patients showed an initial improvement of their individual total disability scores exceeding 25 per cent, but after six years of sustained treatment only 37 patients still obtained similar benefit. By 1978 only five patients had maintained their initial improvement compared to 69 patients after two years therapy; however, 47 patients were still better than before treatment. The overall mortality ratio--the ratio of observed to expected death rate--for all the patients was 1.45:1. In those patients who unable to tolerate levodopa for longer than two years the ratio was 2.38:1; in those who were able to tolerate sustained medication, life expectancy was normal (ratio of 0.91:1 for males and 1.14:1 for females). Involuntary movements were the commonest complication of treatment. Three main types were distinguished. Peak dose dyskinesias, beginning 20 to 90 minutes after an oral dose and most severe midway through the inter-dose period, affected 80 per cent of patients. Early morning and end-of-dose dystonia occurred in 20 per cent of patients and biphasic dyskinesia--two distinct episodes of involuntary movements within each inter-dose period--was the least common pattern affecting 3 per cent of patients. Involuntary movements increased in frequency and severity as treatment continued. End-of-dose deterioration ('wearing- off' effect of individual doses) occurred in 65 per cent of patients: unpredictable oscillations in motor performance (the 'on-off' phenomenon) unrelated to the time and dosage of levodopa, occurred in 10 per cent. Psychiatric side effects included toxic confusional states, visual pseudohallucinations and paranoid psychoses and constituted the most frequent reason for stopping medication. Forty (22 per cent) of the patients had suffered severe depression before the onset of disease and levodopa had no sustained antidepressant effect in this group. After six years of treatment with levodopa, 32 per cent of the patients had unequivocal dementia. PMID- 0007465763&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Shaw KM, Lees AJ, Stern GM</AU>
<TI>The impact of treatment with levodopa on Parkinson's disease</TI>
<SO>The Quarterly Journal of Medicine</SO>
<YR>1980</YR>
<VL>49</VL>
<NO>195</NO>
<PG>283-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="640"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-UPDRS-1987" NAME="UPDRS 1987" NOTES="&lt;p&gt;UPDRS&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Fahn S, Elton RL</AU>
<TI>Unified Parkinson's Disease Rating Scale</TI>
<SO>Recent Developments in Parkinson's Disesase</SO>
<YR>1987</YR>
<VL>II</VL>
<ED>Fahn S, Goldstein M, Marsden D, Calne DB</ED>
<PB>MacMillan</PB>
<CY>New Jersey</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="663"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Watts-1997" NAME="Watts 1997" NOTES="&lt;p&gt;EARLY MONO - 97365446 0 (Antiparkinson Agents) 0 (Dopamine Agonists) 0 (Levodopa) JOURNAL ARTICLE REVIEW REVIEW LITERATURE 0028-3878 A M NZ0 199710 BROMOCRIPTINE&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Watts RL</AU>
<TI>The role of dopamine agonists in early Parkinson's disease</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>49</VL>
<NO>1:Suppl 1</NO>
<PG>S34-S48</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="352"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Webster-1968" NAME="Webster 1968" TYPE="JOURNAL_ARTICLE">
<AU>Webster DD</AU>
<TI>Critical analysis of the disability in Parkinson's disease</TI>
<SO>Modern Treatment</SO>
<YR>1968</YR>
<VL>5</VL>
<NO>2</NO>
<PG>257-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yahr-1969" NAME="Yahr 1969" TYPE="JOURNAL_ARTICLE">
<AU>Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM</AU>
<TI>Treatment of parkinsonism with levodopa</TI>
<SO>Archives of Neurology</SO>
<YR>1969</YR>
<VL>21</VL>
<NO>4</NO>
<PG>343-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-1993" NAME="Zhang 1993" NOTES="&lt;p&gt;94097473 JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL 0251-5350 M NXY 199404 Comparison of Parkinson's disease (PD) prevalence and incidence in various parts of the world is difficult because methods of case ascertainment, diagnostic criteria, classification, medical facilities, and age distribution of the populations vary broadly in different studies. We minimized these differences by adjusting available data to a single standard population. Using this we calculated age-adjusted rates for 27 regional populations and analyzed PD frequency from 45 communities. We conclude: (1) with the exception of China, Japan and Africa, which have the lowest prevalence ratios, the actual prevalence variation for PD is probably lower than previously reported in geographically diverse populations; (2) geographic variation is unlikely to be due exclusively to racial factors, and (3) environmental risk factors for PD might differ regionally&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Zhang ZX, Roman GC</AU>
<TI>Worldwide occurrence of Parkinson's disease: an updated review</TI>
<SO>Neuroepidemiology</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>4</NO>
<PG>195-208</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="642"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Hely-1994">
<CHAR_METHODS>
<P>Randomised: randomisation tables.<BR/>'Double blind': only in titration phase.<BR/>Duration: 5 years (on going), including a 6-month dose titration.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Australia.<BR/>Centres: 4.<BR/>Inclusion criteria: idiopathic PD, receiving no or less than 3 months LD.<BR/>Exclusion criteria: NA.<BR/>No. Randomised: 149.<BR/>Excluded patients: 13 revised diagnoses and 10 failed to complete dose titration phase.<BR/>Mean age: 62 years (BR), 62 years (LD).<BR/>Female:Male = 56:70.<BR/>Mean disease duration: 22 months (BR), 25 months (LD).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) BR monotherapy (start: 1mg/day increased at weekly, then monthly intervals to a max. of 30 mg/day after 40 weeks) [62].<BR/>Mean dose: 32 mg/day, range 7.5-60 mg/day.<BR/>2) LD/carbidopa monotherapy (start: 20/5 mg/day LD increased at weekly, then monthly intervals to a max. of 600/150 mg LD after 40 weeks) [64].<BR/>Mean dose: 475 mg/day, range 300-600 mg/day.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dyskinesias: significant more in LD-group at 1-2-3-4-5 year(s).<BR/>Dystonia: significant more in LD-group at 1-2-3-4-5 year(s).<BR/>Wearing-off: significant more in BR-group at 2 years and significant more in LD-group at 4-5 years.<BR/>On-off fluctuations: 1 patient in the LD-group at 5 years.<BR/>IMP: mod. CURS: NS.<BR/>DIS: mod. NUDS: NS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>LD:carbidopa = 4:1.<BR/>Trial design allowed switching from or addition of therapy.<BR/>Dropouts: 20 (BR), 11 (LD).<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Herskovits-1988">
<CHAR_METHODS>
<P>Randomised: unclear.<BR/>'Single blind'.<BR/>Duration: follow up varied between 18-45 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Argentina.<BR/>Centres: NA.<BR/>Inclusion criteria: recently diagnosed idiopathic PD, prior to trial not receiving any antiparkinsonian medication.<BR/>No. Randomised: 86. BR/LD combination treatment: 31. <BR/>Mean age: 67.5 years.<BR/>Female:Male = 52:34. <BR/>Mean disease duration: NA.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) BR monotherapy (start: 1.25 mg/day increased with 1.25 mg/day to a max. of 15 mg/day) [26].<BR/>Mean daily dose: 12.6 mg, range: 7.5-20 mg. <BR/>2) LD/carbidopa monotherapy (start: 125/12.5 mg/day increased with 125/12.5 mg [29].<BR/>Mean daily dose: 556.1 mg, range: 250-625 mg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dyskinesias: 1 patient on a low dose of BR and 1 patient in the LD-group.<BR/>Dystonia: 2 patients in the LD-group.<BR/>Wearing-off: NA.<BR/>On-off fluctuations: NA.<BR/>IMP: Webster: NS.<BR/>DIS: no scale used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>LD:carbidopa = 10:1.<BR/>Third group on BR/LD combination therapy [29].<BR/>After a mean of 16.3 months 14 patients on BR used additionally LD.<BR/>Dropouts: 2 (BR), 1 (LD).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Olanow-1987">
<CHAR_METHODS>
<P>Randomised: unclear.<BR/>'Single blind'.<BR/>Duration: mean 17.2 months (all patients completed first 6 months).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA.<BR/>Centres: NA.<BR/>Inclusion criteria: idiopathic PD and functional disability.<BR/>Exclusion criteria: previous therapy of LD or dopamine agonists, Parkinson's Plus syndromes, drug-induced parkinsonism, dementia, significant neurological or medical disease.<BR/>No. Randomised: 47.<BR/>Mean age: 60.6 years (BR), 63.8 years (LD).<BR/>Female:Male = 8:15 (BR), 10:14 (LD).<BR/>Mean disease duration: 1.3 years (BR), 1.5 years (LD).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) BR monotherapy (start: 1.25 mg/day, increased with 1.25 mg/week) [23].<BR/>Mean dose: 10.9 mg/day (6 months), 16.8 mg/day (15 months).<BR/>2) LD/carbidopa monotherapy (start: 50/12.5 mg/day increased with 50/12.5 mg/week) [24].<BR/>Mean dose: 322.9 mg/day (6 months), 383.3 mg/day (15 months).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dyskinesias: absent.<BR/>Dystonia: significant more in LD-group at 1-2 year(s).<BR/>Wearing-off: 1 patient in the LD-group at 6 months.<BR/>On-off fluctuations: absent.<BR/>IMP &amp; DIS: TP score: NS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>LD:carbidopa = 4:1.<BR/>After a mean of 17 months, 5 patients on BR used additionally LD. <BR/>After 18 months, 1 patient on LD used additionally BR.<BR/>Dropouts: 1 (BR), 4 (LD).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Riopelle-1988">
<CHAR_METHODS>
<P>Randomised: unclear.<BR/>'Double blind'.<BR/>Duration: 2-week baseline, 15-week titration and a 6-week maintenance phase (= pilot study, trial on going).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Canada.<BR/>Centres: 7.<BR/>Inclusion criteria: idiopathic PD.<BR/>Exclusion criteria: previously antiparkinsonism therapy other than anticholinergics.<BR/>No. Randomised: 81.<BR/>Mean age: 66.5 years (BR), 66.2 years (LD).<BR/>Mean disease duration: NA.<BR/>Female:Male = 13:29 (BR), 19:20 (LD).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) BR monotherapy (start: 5 mg/day increased every 3rd week to a max. of 30 mg/day [42].<BR/>Mean dose: 26.1 mg/day.<BR/>2) LD monotherapy (start: 50 mg/day increased every 3rd week to a max. of 300 mg/day [39].<BR/>Mean dose: 262.8 mg/day (plain LD).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dyskinesias were absent.<BR/>Dystonia: NA.<BR/>Wearing-off: NA.<BR/>On-off fluctuations: NA.<BR/>IMP: CURS: NS.<BR/>DIS: NUDS: NS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>LD:carbidopa = 4:1. <BR/>No change in treatment regime allowed.<BR/>Dropouts: 4 (BR), 0 (LD).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-UK_x002d_PDRG-1993">
<CHAR_METHODS>
<P>Randomised: random number tables.<BR/>'Open study'.<BR/>Duration: &gt; 72 months (on going).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK.<BR/>Centres: 93.<BR/>Inclusion criteria: PD (according to the criteria of the PD Society of the UK Brain Tissue Bank), incapacity, which in the judgement of the clinician was sufficient to merit dopaminergic treatment.<BR/>Exclusion criteria: previously failed to respond to dopaminergic drugs, incapacitating cognitive impairment.<BR/>No. Randomised: 782.<BR/>Selegine treatment: 271.<BR/>Mean age: 62.1 years (BR), 62.7 years (LD).<BR/>Female:Male = 114:148 (BR), 111:138 (LD).<BR/>Mean disease duration: 14 months (1-144).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) BR monotherapy (start: 2.5 mg/day increased with 2.5 mg/ 3rd day to a max. of 120 mg/d [262].<BR/>Mean dose: NA, range: 7.5 -120 mg/day.<BR/>2) LD/benserazide monotherapy (start: 150/37.5 mg/day increased to a max. of 300/75 mg/day [249].<BR/>Mean dose: NA, range: NA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dyskinesias: statistically significant more in LD-group at 3 years.<BR/>Dystonia: statistically significant more in LD-group at 3 years.<BR/>Wearing-off: NA.<BR/>On-off fluctuations: statistically significant more in LD-group at 3 years.<BR/>IMP: mod. Webster statistically significant in favour of LD-group during first year of follow up. <BR/>DIS: NUDS: no results reported; the trend was similar with Webster.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>LD:benserazide = 4:1.<BR/>Intention to treat.<BR/>No change in treatment regime.<BR/>Dropouts: 181 (BR), 80 (LD).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Weiner-1993">
<CHAR_METHODS>
<P>Randomised: computerised random allocation.<BR/>'Double blind'. <BR/>Duration: 4 years.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA.<BR/>Centres: NA.<BR/>Inclusion criteria: PD. <BR/>Exclusion criteria: previously treated with BR or LD.<BR/>No. Randomised: 25.<BR/>Excluded patients: 1 lost to follow up (BR), 1 orthostatic hypotension (BR), 1 revised diagnosis (LD).<BR/>Mean age: 60.3 years (BR), 65.7 years (LD).<BR/>Female:Male = 11:14.<BR/>Mean disease duration: 34 months (BR), 11.6 months (LD).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) BR monotherapy (start 1.25 mg/day increased to a max. of 30 mg/day [6].<BR/>Mean dose: 18 mg, range 6.25-30 mg.<BR/>2) LD/carbidopa monotherapy (start 50/12.5 mg/d increased to a max. of 1200/300 mg/day [9].<BR/>Mean dose: 417 mg, range 150-700.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dyskinesias: significant more in LD-group at 1-2-3 year(s).<BR/>Dystonia: significant more in LD-group at 1-2-3 year(s), only statistically significant at 3 years.<BR/>Wearing-off: NA.<BR/>On-off fluctuations: NA. <BR/>IMP: mod. CURS: NS.<BR/>DIS: ADL scale: significant difference in favour of BR at 1 moment (48 months).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>LD:carbidopa = 4:1.<BR/>No change in treatment regime.<BR/>Dropouts: 1 (BR), 1 (LD).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADL: Activities-of-daily-living (scale)<BR/>BR: bromocriptine<BR/>CURS: Columbia University Rating Scale<BR/>DIS: disability<BR/>IMP: impairment<BR/>LD: levodopa<BR/>max.: maximum<BR/>(mod.) NUDS: (modified) Northwestern University Disability Scale<BR/>(mod.) CURS: (modified) Columbia University Rating Scale<BR/>NA: not available<BR/>NS: not significant<BR/>TP: Total Parkinson's score, a combination of the modified England-Schwab Disability Scale, a modified Columbia Scale and the Hoehn and Yahr stage with a maximum total score of 420<BR/>[X]: number of patients</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Caraceni-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Bromocriptine or lisuride could be used. Results not split.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gawel-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Identical to included study of Riopelle 1988.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Libman-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Identical to included study of Riopelle 1988.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Riopelle-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Identical to included study of Riopelle 1988.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wallis-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lack of final results.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hely-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Herskovits-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Olanow-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Riopelle-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-UK_x002d_PDRG-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Weiner-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Occurrence of dyskinesias</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="39" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>At one year</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.274707694166097" CI_START="0.018844120673917244" EFFECT_SIZE="0.20703832081707474" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.35692559661210266" LOG_CI_START="-1.7248241232913415" LOG_EFFECT_SIZE="-0.6839492633396195" ORDER="35" O_E="-1.053191489361702" SE="1.2228300902985907" STUDY_ID="STD-Hely-1994" TOTAL_1="33" TOTAL_2="61" VAR="0.6687561150133617" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.320096013351039" CI_START="0.0034567501408030686" EFFECT_SIZE="0.18887560283756188" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.0136837377829149" LOG_CI_START="-2.4613320107937544" LOG_EFFECT_SIZE="-0.7238241365054197" ORDER="36" O_E="-0.4" SE="2.0412414523193148" STUDY_ID="STD-Weiner-1993" TOTAL_1="6" TOTAL_2="9" VAR="0.24000000000000002" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>At two years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1923008017166083" CI_START="0.043508933383653164" EFFECT_SIZE="0.2277624555434108" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.07638583597917617" LOG_CI_START="-1.3614215632545514" LOG_EFFECT_SIZE="-0.6425178636376877" ORDER="37" O_E="-2.074074074074074" SE="0.8445751835713036" STUDY_ID="STD-Hely-1994" TOTAL_1="21" TOTAL_2="60" VAR="1.4019204389574758" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.7705686628397963" CI_START="0.00814200138138228" EFFECT_SIZE="0.15019312194656614" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.44256891772383095" LOG_CI_START="-2.0892688282736604" LOG_EFFECT_SIZE="-0.8233499552749146" ORDER="38" O_E="-0.8571428571428571" SE="1.4872140247978956" STUDY_ID="STD-Weiner-1993" TOTAL_1="6" TOTAL_2="8" VAR="0.4521193092621665" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="275" TOTAL_2="314" WEIGHT="0.0" Z="0.0">
<NAME>At three years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5986906635750848" CI_START="0.03693267408532811" EFFECT_SIZE="0.24298954965404487" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="14" LOG_CI_END="0.20376443866879884" LOG_CI_START="-1.4325892464118946" LOG_EFFECT_SIZE="-0.6144124038715479" ORDER="39" O_E="-1.53125" SE="0.961202254697777" STUDY_ID="STD-Hely-1994" TOTAL_1="7" TOTAL_2="57" VAR="1.0823567708333333" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.2094823290099998" CI_START="0.07735964673556994" EFFECT_SIZE="0.12730074221919532" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="67" LOG_CI_END="-0.6788526062877924" LOG_CI_START="-1.1114855221352786" LOG_EFFECT_SIZE="-0.8951690642115355" ORDER="40" O_E="-31.915851272015658" SE="0.2541307163362857" STUDY_ID="STD-UK_x002d_PDRG-1993" TOTAL_1="262" TOTAL_2="249" VAR="15.484089706439905" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1827456367766174" CI_START="0.030903684983908938" EFFECT_SIZE="0.25972077999063975" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3390031287550791" LOG_CI_START="-1.5099897318127358" LOG_EFFECT_SIZE="-0.5854933015288284" ORDER="41" O_E="-1.1428571428571428" SE="1.0861075589598066" STUDY_ID="STD-Weiner-1993" TOTAL_1="6" TOTAL_2="8" VAR="0.847723704866562" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3" TOTAL_2="52" WEIGHT="0.0" Z="0.0">
<NAME>At four years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6205419514931843" CI_START="0.015489015947259748" EFFECT_SIZE="0.1584316891593389" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="24" LOG_CI_END="0.20966027823535066" LOG_CI_START="-1.809976173089765" LOG_EFFECT_SIZE="-0.8001579474272071" ORDER="42" O_E="-1.309090909090909" SE="1.1863444488700423" STUDY_ID="STD-Hely-1994" TOTAL_1="3" TOTAL_2="52" VAR="0.7105234159779614" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>At five years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1120319304977047" CI_START="0.0033127967896822443" EFFECT_SIZE="0.060695434831434754" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="35" LOG_CI_END="0.04611725760563049" LOG_CI_START="-2.4798052033653626" LOG_EFFECT_SIZE="-1.2168439728798661" ORDER="43" O_E="-1.2727272727272727" SE="1.4837393570921973" STUDY_ID="STD-Hely-1994" TOTAL_1="2" TOTAL_2="53" VAR="0.45423936333027237" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Occurrence of dystonia</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="94" WEIGHT="0.0" Z="0.0">
<NAME>At one year</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0994726676239523" CI_START="0.035017418902165476" EFFECT_SIZE="0.19621593965238732" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.04118443747339979" LOG_CI_START="-1.455715868471249" LOG_EFFECT_SIZE="-0.7072657154989246" ORDER="44" O_E="-2.106382978723404" SE="0.8792866494879044" STUDY_ID="STD-Hely-1994" TOTAL_1="33" TOTAL_2="61" VAR="1.2934184202456227" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.228255457606685" CI_START="0.008189334213711229" EFFECT_SIZE="0.1350848942549358" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.34796497890256256" LOG_CI_START="-2.086751404596693" LOG_EFFECT_SIZE="-0.8693932128470654" ORDER="45" O_E="-0.9787234042553191" SE="1.4301644557079338" STUDY_ID="STD-Olanow-1987" TOTAL_1="23" TOTAL_2="24" VAR="0.488909008601177" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.2124906246323963" CI_START="0.058794133557720465" EFFECT_SIZE="0.43459820850707837" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.5068418688914575" LOG_CI_START="-1.230666005396877" LOG_EFFECT_SIZE="-0.3619120682527097" ORDER="46" O_E="-0.7999999999999998" SE="1.0206207261596574" STUDY_ID="STD-Weiner-1993" TOTAL_1="6" TOTAL_2="9" VAR="0.9600000000000001" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="92" WEIGHT="0.0" Z="0.0">
<NAME>At two years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.057381077599609" CI_START="0.08316206367256032" EFFECT_SIZE="0.2965366629971733" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="0.02423153420640537" LOG_CI_START="-1.080074742158207" LOG_EFFECT_SIZE="-0.5279216039759009" ORDER="47" O_E="-2.888888888888889" SE="0.6486749731408025" STUDY_ID="STD-Hely-1994" TOTAL_1="21" TOTAL_2="60" VAR="2.376543209876543" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8070837449631179" CI_START="0.03974350254503707" EFFECT_SIZE="0.17909867356292655" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.09308139949306506" LOG_CI_START="-1.40073386171155" LOG_EFFECT_SIZE="-0.7469076306023075" ORDER="48" O_E="-2.9148936170212765" SE="0.7681215292912208" STUDY_ID="STD-Olanow-1987" TOTAL_1="23" TOTAL_2="24" VAR="1.6948845631507468" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9398743885561901" CI_START="0.013306901884947878" EFFECT_SIZE="0.11183387801866035" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="-0.026930184700438644" LOG_CI_START="-1.8759230452682536" LOG_EFFECT_SIZE="-0.9514266149843461" ORDER="49" O_E="-1.8571428571428572" SE="1.0861075589598066" STUDY_ID="STD-Weiner-1993" TOTAL_1="6" TOTAL_2="8" VAR="0.8477237048665621" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="88" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="276" TOTAL_2="314" WEIGHT="0.0" Z="0.0">
<NAME>At three years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2947410650055509" CI_START="0.03806770048054871" EFFECT_SIZE="0.2220085923168244" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="17" LOG_CI_END="0.11218292263862874" LOG_CI_START="-1.4194433564078794" LOG_EFFECT_SIZE="-0.6536302168846254" ORDER="50" O_E="-1.859375" SE="0.8996848579842759" STUDY_ID="STD-Hely-1994" TOTAL_1="7" TOTAL_2="57" VAR="1.2354329427083333" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.40300959745011755" CI_START="0.1560389218364462" EFFECT_SIZE="0.25076918286714683" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="63" LOG_CI_END="-0.39468461125344323" LOG_CI_START="-0.8067670591427358" LOG_EFFECT_SIZE="-0.6007258351980895" ORDER="51" O_E="-23.607421875" SE="0.24205926973118563" STUDY_ID="STD-UK_x002d_PDRG-1993" TOTAL_1="263" TOTAL_2="249" VAR="17.066975401338997" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.4604861941312963" CI_START="0.005035742667178713" EFFECT_SIZE="0.04815485412119642" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.3367833858851028" LOG_CI_START="-2.297936470994624" LOG_EFFECT_SIZE="-1.3173599284398636" ORDER="52" O_E="-2.2857142857142856" SE="1.1519910300576708" STUDY_ID="STD-Weiner-1993" TOTAL_1="6" TOTAL_2="8" VAR="0.7535321821036107" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3" TOTAL_2="52" WEIGHT="0.0" Z="0.0">
<NAME>At four years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.149613608681" CI_START="0.01779167953483579" EFFECT_SIZE="0.19556389352171905" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="20" LOG_CI_END="0.33236040284656543" LOG_CI_START="-1.7497830525747609" LOG_EFFECT_SIZE="-0.7087113248640976" ORDER="53" O_E="-1.0909090909090908" SE="1.2230613724908168" STUDY_ID="STD-Hely-1994" TOTAL_1="3" TOTAL_2="52" VAR="0.6685032139577595" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>At five years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.959094786612788" CI_START="0.010180899657165616" EFFECT_SIZE="0.17356914212655056" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="23" LOG_CI_END="0.4711588768347038" LOG_CI_START="-1.9922138429345364" LOG_EFFECT_SIZE="-0.7605274830499162" ORDER="54" O_E="-0.8363636363636363" SE="1.446997329484075" STUDY_ID="STD-Hely-1994" TOTAL_1="2" TOTAL_2="53" VAR="0.4776002448729721" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Occurrence of on/off-fluctuations</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At one year</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At two years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="82" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="263" TOTAL_2="249" WEIGHT="0.0" Z="0.0">
<NAME>At three years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2458311540882023" CI_START="0.10087726678560269" EFFECT_SIZE="0.15747626778396862" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="82" LOG_CI_END="-0.6093630799880927" LOG_CI_START="-0.9962066932471406" LOG_EFFECT_SIZE="-0.8027848866176166" ORDER="55" O_E="-35.798828125" SE="0.22723385333513368" STUDY_ID="STD-UK_x002d_PDRG-1993" TOTAL_1="263" TOTAL_2="249" VAR="19.366624574605265" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At four years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>At five years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="14995.788532221906" CI_START="8.391829963009695E-6" EFFECT_SIZE="0.3547423114369882" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="4.175969307453923" LOG_CI_START="-5.076143324489754" LOG_EFFECT_SIZE="-0.45008700851791555" ORDER="56" O_E="-0.03508771929824561" SE="5.434736758699876" STUDY_ID="STD-Hely-1994" TOTAL_1="2" TOTAL_2="55" VAR="0.03385657125269313" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Occurrence of wearing-off</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="61" WEIGHT="0.0" Z="0.0">
<NAME>At one year</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="57" O_E="0.0" SE="0.0" STUDY_ID="STD-Hely-1994" TOTAL_1="33" TOTAL_2="61" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At two years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="138.97587988747495" CI_START="1.455766596080918" EFFECT_SIZE="14.223798494113305" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="2.142939432335101" LOG_CI_START="0.16309174986732353" LOG_EFFECT_SIZE="1.1530155911012123" ORDER="58" O_E="1.962962962962963" SE="1.1629723290856597" STUDY_ID="STD-Hely-1994" TOTAL_1="21" TOTAL_2="60" VAR="0.7393689986282578" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="7" TOTAL_2="57" WEIGHT="0.0" Z="0.0">
<NAME>At three years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.14523876087488" CI_START="0.23437354405718785" EFFECT_SIZE="1.5420037495715109" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="1.006262272296943" LOG_CI_START="-0.6300914127837505" LOG_EFFECT_SIZE="0.18808542975659628" ORDER="59" O_E="0.46875" SE="0.961202254697777" STUDY_ID="STD-Hely-1994" TOTAL_1="7" TOTAL_2="57" VAR="1.0823567708333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3" TOTAL_2="52" WEIGHT="0.0" Z="0.0">
<NAME>At four years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4940907982926452" CI_START="0.018292898755231934" EFFECT_SIZE="0.21359810499984067" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="18" LOG_CI_END="0.3969122600806406" LOG_CI_START="-1.7377174692829878" LOG_EFFECT_SIZE="-0.6704026046011735" ORDER="60" O_E="-0.9818181818181818" SE="1.2538920696157714" STUDY_ID="STD-Hely-1994" TOTAL_1="3" TOTAL_2="52" VAR="0.6360330578512396" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>At five years</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3861238803101106" CI_START="0.008788232398264106" EFFECT_SIZE="0.14480956871427034" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="26" LOG_CI_END="0.37769298717107624" LOG_CI_START="-2.0560984670053744" LOG_EFFECT_SIZE="-0.8392027399171489" ORDER="61" O_E="-0.9454545454545454" SE="1.429621147645244" STUDY_ID="STD-Hely-1994" TOTAL_1="2" TOTAL_2="53" VAR="0.489280685644322" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Withdrawal rate</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="197" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="418" TOTAL_2="405" WEIGHT="0.0" Z="0.0">
<NAME>All causes</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.984331644942071" CI_START="0.9350074153308591" EFFECT_SIZE="2.15879296100601" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.6976069314794512" LOG_CI_START="-0.029184944823200654" LOG_EFFECT_SIZE="0.3342109933281253" ORDER="62" O_E="4.222222222222221" SE="0.426921145817988" STUDY_ID="STD-Hely-1994" TOTAL_1="62" TOTAL_2="64" VAR="5.486617283950617" WEIGHT="0.0"/>
<DICH_DATA CI_END="20.759939066998832" CI_START="0.2065760970267176" EFFECT_SIZE="2.070871117904998" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3172260744700133" LOG_CI_START="-0.6849199322353937" LOG_EFFECT_SIZE="0.3161530711173098" ORDER="63" O_E="0.5263157894736843" SE="1.1760704751213285" STUDY_ID="STD-Herskovits-1988" TOTAL_1="28" TOTAL_2="29" VAR="0.7229916897506925" WEIGHT="0.0"/>
<DICH_DATA CI_END="17.228919594600477" CI_START="0.0633201100078922" EFFECT_SIZE="1.044479336342865" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2362580442028248" LOG_CI_START="-1.1984583392964308" LOG_EFFECT_SIZE="0.018899852453197082" ORDER="64" O_E="0.021276595744680882" SE="1.4301644557079338" STUDY_ID="STD-Olanow-1987" TOTAL_1="23" TOTAL_2="24" VAR="0.488909008601177" WEIGHT="0.0"/>
<DICH_DATA CI_END="54.75466038131135" CI_START="1.0045690706008172" EFFECT_SIZE="7.4165246773888205" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7384210895715229" LOG_CI_START="0.001979802656722029" LOG_EFFECT_SIZE="0.8702004461141226" ORDER="65" O_E="1.925925925925926" SE="1.0199942074567512" STUDY_ID="STD-Riopelle-1988" TOTAL_1="42" TOTAL_2="39" VAR="0.9611796982167352" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.741066664025181" CI_START="3.858992271405287" EFFECT_SIZE="5.465593877055473" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="58" LOG_CI_END="0.8888008075023615" LOG_CI_START="0.5864739087892257" LOG_EFFECT_SIZE="0.7376373581457936" ORDER="66" O_E="53.85546875" SE="0.1775883168463805" STUDY_ID="STD-UK_x002d_PDRG-1993" TOTAL_1="263" TOTAL_2="249" VAR="31.708172912000443" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="286" TOTAL_2="273" WEIGHT="0.0" Z="0.0">
<NAME>Lost to follow up</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.228919594600477" CI_START="0.0633201100078922" EFFECT_SIZE="1.044479336342865" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2362580442028248" LOG_CI_START="-1.1984583392964308" LOG_EFFECT_SIZE="0.018899852453197082" ORDER="67" O_E="0.021276595744680882" SE="1.4301644557079338" STUDY_ID="STD-Olanow-1987" TOTAL_1="23" TOTAL_2="24" VAR="0.488909008601177" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6084683058153668" CI_START="0.09283684905389675" EFFECT_SIZE="0.23767263254540155" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.2157620385809616" LOG_CI_START="-1.032279608217499" LOG_EFFECT_SIZE="-0.6240208233992304" ORDER="68" O_E="-6.24609375" SE="0.4796264622316575" STUDY_ID="STD-UK_x002d_PDRG-1993" TOTAL_1="263" TOTAL_2="249" VAR="4.347040911709959" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="263" TOTAL_2="249" WEIGHT="0.0" Z="0.0">
<NAME>Poor compliance</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3006675334382107" CI_START="0.29519385650058855" EFFECT_SIZE="0.8241012812278126" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.36185386385534823" LOG_CI_START="-0.5298926851811694" LOG_EFFECT_SIZE="-0.08401941066291055" ORDER="69" O_E="-0.705078125" SE="0.5238163371206597" STUDY_ID="STD-UK_x002d_PDRG-1993" TOTAL_1="263" TOTAL_2="249" VAR="3.64453328798895" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="263" TOTAL_2="249" WEIGHT="0.0" Z="0.0">
<NAME>Protocol violation</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.27511186553778405" CI_START="0.04988074774134167" EFFECT_SIZE="0.1171442937813879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="22" LOG_CI_END="-0.560490678143738" LOG_CI_START="-1.302067044818504" LOG_EFFECT_SIZE="-0.931278861481121" ORDER="70" O_E="-11.30078125" SE="0.4356056286469756" STUDY_ID="STD-UK_x002d_PDRG-1993" TOTAL_1="263" TOTAL_2="249" VAR="5.270029355401863" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="263" TOTAL_2="249" WEIGHT="0.0" Z="0.0">
<NAME>Lack of response</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.710848393260235" CI_START="3.6474818707154397" EFFECT_SIZE="6.809007936243663" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="2" LOG_CI_END="1.1041745387691804" LOG_CI_START="0.5619931419725318" LOG_EFFECT_SIZE="0.833083840370856" ORDER="71" O_E="18.912109375" SE="0.31848003631954996" STUDY_ID="STD-UK_x002d_PDRG-1993" TOTAL_1="263" TOTAL_2="249" VAR="9.859061410982314" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="263" TOTAL_2="249" WEIGHT="0.0" Z="0.0">
<NAME>Deterioration</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.878369680916876" CI_START="1.3620935897655733" EFFECT_SIZE="2.5777501955937474" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="11" LOG_CI_END="0.6882747078881031" LOG_CI_START="0.13420694907628" LOG_EFFECT_SIZE="0.41124082848219157" ORDER="72" O_E="8.939453125" SE="0.3254621442057043" STUDY_ID="STD-UK_x002d_PDRG-1993" TOTAL_1="263" TOTAL_2="249" VAR="9.440587836935562" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="93" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="561" TOTAL_2="548" WEIGHT="0.0" Z="0.0">
<NAME>Adverse reaction</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="6" I2="0.0" ID="CMP-005.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Hallucinations/confusion</NAME>
<DICH_DATA CI_END="5.2028423311742715" CI_START="0.6437873527853124" EFFECT_SIZE="1.8301705088177025" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.7162406650775641" LOG_CI_START="-0.19125755928989144" LOG_EFFECT_SIZE="0.2624915528938363" ORDER="73" O_E="2.1269841269841274" SE="0.533068949182103" STUDY_ID="STD-Hely-1994" TOTAL_1="62" TOTAL_2="64" VAR="3.5191131267321736" WEIGHT="0.0"/>
<DICH_DATA CI_END="347.6480898152931" CI_START="0.13614321786184416" EFFECT_SIZE="6.879675110859336" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5411398474568374" LOG_CI_START="-0.8660039886871516" LOG_EFFECT_SIZE="0.8375679293848429" ORDER="74" O_E="0.4814814814814815" SE="2.0013731549849734" STUDY_ID="STD-Riopelle-1988" TOTAL_1="42" TOTAL_2="39" VAR="0.24965706447187927" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-005.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="104" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="4.3069776317755535" CI_START="0.24833890320019952" EFFECT_SIZE="1.0342098922283298" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.634172616266507" LOG_CI_START="-0.6049552412922372" LOG_EFFECT_SIZE="0.014608687487134881" ORDER="75" O_E="0.06349206349206371" SE="0.7278698373118256" STUDY_ID="STD-Hely-1994" TOTAL_1="62" TOTAL_2="64" VAR="1.887524313429075" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.63605121536986" CI_START="0.7293843186581291" EFFECT_SIZE="7.2284308398905885" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8551316382791672" LOG_CI_START="-0.13704357800256625" LOG_EFFECT_SIZE="0.8590440301383004" ORDER="76" O_E="1.4444444444444444" SE="1.1702135834702538" STUDY_ID="STD-Riopelle-1988" TOTAL_1="42" TOTAL_2="39" VAR="0.7302469135802468" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-005.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="64" WEIGHT="0.0" Z="0.0">
<NAME>Orthostase</NAME>
<DICH_DATA CI_END="58.346370259318405" CI_START="1.1030356895133862" EFFECT_SIZE="8.022351821603849" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.766013843665346" LOG_CI_START="0.0425895645779692" LOG_EFFECT_SIZE="0.9043017041216576" ORDER="77" O_E="2.0317460317460316" SE="1.0123479526236943" STUDY_ID="STD-Hely-1994" TOTAL_1="62" TOTAL_2="64" VAR="0.9757540942302845" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="71" EVENTS_2="7" I2="0.0" ID="CMP-005.07.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="291" TOTAL_2="278" WEIGHT="0.0" Z="0.0">
<NAME>Other/unclear</NAME>
<DICH_DATA CI_END="20.759939066998832" CI_START="0.2065760970267176" EFFECT_SIZE="2.070871117904998" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3172260744700133" LOG_CI_START="-0.6849199322353937" LOG_EFFECT_SIZE="0.3161530711173098" ORDER="78" O_E="0.5263157894736843" SE="1.1760704751213285" STUDY_ID="STD-Herskovits-1988" TOTAL_1="28" TOTAL_2="29" VAR="0.7229916897506925" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.930993133940873" CI_START="4.105452792784006" EFFECT_SIZE="6.699005619466246" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="6" LOG_CI_END="1.0386596215102055" LOG_CI_START="0.6133610626888512" LOG_EFFECT_SIZE="0.8260103420995283" ORDER="79" O_E="30.474609375" SE="0.24982247871348295" STUDY_ID="STD-UK_x002d_PDRG-1993" TOTAL_1="263" TOTAL_2="249" VAR="16.02274695021299" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="263" TOTAL_2="249" WEIGHT="0.0" Z="0.0">
<NAME>Revised diagnosis</NAME>
<GROUP_LABEL_1>BR</GROUP_LABEL_1>
<GROUP_LABEL_2>LD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BR</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LD</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5655930336883714" CI_START="0.6846813598155157" EFFECT_SIZE="1.3253730520268503" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.4091877676894802" LOG_CI_START="-0.16451149547057853" LOG_EFFECT_SIZE="0.12233813610945077" ORDER="80" O_E="2.48046875" SE="0.33699378703737176" STUDY_ID="STD-UK_x002d_PDRG-1993" TOTAL_1="263" TOTAL_2="249" VAR="8.80554441089966" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>